Modern problems of valvular conduits in children with cardiovascular diseases

Right ventricular outflow tract anomaly in young children can occur both in isolation and as part of a group of congenital heart defects. Such patients require radical correction of the defect from an early age, one of the elements of which is the formation of an outflow tract from the right ventricle to the pulmonary artery. Despite the wide variety of valve prostheses and valve-containing conduits on the world market (pulmonary allograft (CryoLife, USA), xenoconduits Contegra (Medtronic Inc., Minneapolis, MN), Freestyle (Medtronic Inc., Minneapolis, MN), ePTFE conduit (W.L. Gore & Associates Inc, Flagstaff, AZ, USA), DP-BYVC (Yaxin Medical Technology Co., Ltd., Wuhan, China)), there is currently no ideal graft that would be free from repeated prosthetics. The problem of choosing the optimal conduit for the reconstruction of the right ventricular outflow tract remains relevant, since one of a number of reasons for the development of RVPA conduit dysfunction is the lack of growth ability as the child grows. However, the development of tissue engineering technologies in cardiovascular surgery may lead to the development of new valve-containing conduits (Xeltis, XeltisXPC), which may become a worthy alternative to existing conduits for RVOT-PA reconstruction and reduce the number of reoperations in the group of patients with RV outflow tract anomalies.